{"id":"W3011435761","doi":"10.1016/j.ejca.2020.02.021","title":"Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":110,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Sandoz; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; InflaRx; Les Laboratories Pierre Fabre; Helsinn; OncoSec Medical; Roche; CureVac; Regeneron Pharmaceuticals; Novartis; Alcedis; Bristol-Myers Squibb; Sanofi; Merck; Boehringer Ingelheim; Amgen; Array BioPharma","keywords":"Medicine; Oncology; Melanoma; Blockade; Clinical trial; Internal medicine; Survival analysis; Progression-free survival; MEK inhibitor; Kinase; Cancer research; Overall survival; MAPK/ERK pathway; Biology; Receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000311972,0.0001223158,0.0002198686,0.00002723474,0.00002686013,0.00000862775,0.00007660507,0.00001480153,0.00002827142],"category_scores_gemma":[0.00003939615,0.00007223303,0.0001147155,0.00006402643,0.0000784177,0.00001484062,0.00005392121,0.00009817012,0.000001284046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001032862,"about_ca_system_score_gemma":0.00008221858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007660631,"about_ca_topic_score_gemma":0.000002642987,"domain_scores_codex":[0.9989778,0.0002173788,0.0004141969,0.0001135673,0.000171128,0.0001059498],"domain_scores_gemma":[0.9988885,0.00000816044,0.0006422117,0.0001187784,0.0002636146,0.00007872815],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001585508,0.00009230882,0.003938453,0.00006729345,0.0002072439,0.00002767813,0.000263925,0.0004166571,0.9868512,0.00001813904,0.000416675,0.00611495],"study_design_scores_gemma":[0.004892762,0.005414873,0.1471454,0.0001753308,0.0001071903,0.00001355336,0.0001311724,0.00001574143,0.8402896,0.00002918727,0.001596356,0.000188845],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963928,0.002319,0.0005749305,0.0001872263,0.00007360502,0.0001193819,0.0001491413,0.000001542323,0.0001823451],"genre_scores_gemma":[0.9993058,0.0002482787,0.0002159108,0.00004522471,0.00009846846,9.925225e-7,0.00005130071,0.00002025678,0.00001371172],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1465616,"threshold_uncertainty_score":0.2945578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009071601066493962,"score_gpt":0.229577607853554,"score_spread":0.2205060067870601,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}